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ABSTRACT 
Objective: Evaluation of different natural and synthetic polymers as protective layer (PL) in the manufacturing of control release (CR) multi-unit 
pellets (MUPS) tablets, highly soluble and high dose drug metoprolol succinate (MS) was selected as model drug. The function of PL is to protect CR 
functional coating layer of pellets from damage during compression of MUPS tablets. 
Methods: MS is highly soluble biopharmaceutics classification system(BCS) Class–I molecule, hence selected aqueous solution layering method for 
drug loading in fluid bed processor (FBP), optimized formulation was manufactured by using seal coating on microcrystalline cellulose (MCC) 
pellets followed by drug loading (DL) and CR coating, applied by using the solution layering method in FBP. Given coating on these functional coated 
pellets with different natural and synthetic polymers like hydroxypropyl cellulose (Klucel LF), polyethylene glycol 6000 (PEG 6000), hypromellose 5 
cps (HPMC 5cps), guar gum (GG) and xanthan gum (XM). Evaluated these pellet’s for physical characterization and chemical characterization. 
Results: Drug release profiles of CR MUPS tablets containing PL coating were compared to those CR pellets and f2 values observed was 81.83, 49.92, 
89.35, 66.44, and 85.25 with Klucel LF, PEG 6000, HPMC 5 cps, GG and XM coated MUPS tablets respectively. The dissolution data indicated that, 
there was no significant change were observed with MUPS containing Klucel LF, HPMC 5 cps, GG and XG PLs whereas faster release profiles were 
observed with PEG 6000PL MUPS tablets. 
Conclusion: Based on these dissolution profiles it was concluded that by applying low viscous natural or synthetic binders like Klucel LF, HPMC 5 
cps, GG and XG on functional coating pellets given good protection to functional coating pellets from damage during compression. It is a very 
effective and potent strategy for manufacturing of MUPS tablets. Whereas PEG 6000 polymer not able to give protection to functional coating pellets 
from damage during compression, it may be due to its very low viscosity of PEG 6000. 
Keywords: MUPS, CR, Compression of pellets, Drug release, Natural and synthetic Polymers 




Pharmaceutical solid dosage forms are using a functional coating to 
modify the release. Due to the disadvantages of coated single-unit 
dosage forms, such as dose dumping, less predictable gastrointestinal 
(GI) transit times and may potentially lodge in restrictions within the 
GI tract, which could lead to variable drug absorption and cause 
damage to the gastric mucosa if the drug is irritant, and hence coated 
MUPS are preferred. Coated MUPS can eventually be filled into 
capsules or compressed into tablets. Tablet dosage form is more 
desirable as unit production costs of considerably lower and 
machinery is more easily available. However, some challenges is there 
in the manufacturing of MUPS tablets, compression forces can result in 
damage of functional coating, segregation pellets during compression. 
Hence, it is important to understand the factors affecting coat damage 
during compression [1-3] and segregation of pellets during manu-
facturing of tablets. 
There are many relevant articles and literature available on the 
preparation of pellets and coating technology. However, only few 
research articles discuss the issue of compaction of pellets into 
tablets [4]. A different techniques were used to prevent the damage 
of functional layers in past work, but remains an unmet need in drug 
delivery, some of techniques are use of cushioning excipients and/or 
compressible excipients, novel granulation techniques to protect the 
coating layer against fracture during compaction [5-10], improved 
by thermal exposure [11], Layering the top surface of beads with 
compressible excipients, such as MCC, to modify the mechanical 
properties of the beads was successful in addressing this issue. This 
approach, however, requires a huge amount of the layering 
excipients, but still with mixed results [12]. 
Natural (GG and XG) and synthetic polymers (Klucel LF, PEG 6000, 
HPMC 5 cps) were evaluated for different activities like binders, 
CR polymers, plasticizers[13-16] but its activity as a PL agent has 
not been evaluated in MUPS tablets. The objective of the present 
study was to evaluate these polymers as PL agents to protect 
pellets from compression force during compression, for this study 
high dose and high soluble drug MS was selected as a model drug, 
MS is a beta1-selective (cardioselective) adrenoceptor blocking 
agent, It is freely soluble in water, Its chemical name is (±)1-
(isopropylamine)-3-[p-(2-methoxyethyl) phenoxy]-2-propanol 
succinate (2:1) (salt). This strategy helps in the easy development 
of MUPS tablets in the overcome big challenge of breaking pellets 
during compression. 
MATERIALS AND METHODS 
Materials 
MS, gifted by CTX Lifesciences (P) Ltd, Gujarat, India, MCC 
spheres(Celphere CP 203) gifted by Asahi Kasei Chemicals, ethocel 
standard 10 premium gifted by Dow Chemicals, acetyltributyl 
citrate gifted by Vertellus Performance Materials Inc. 2110 High 
Point Road, Greensboro, N. C, HPMC 5cps gifted by Dow Chemicals, 
Klucel LF gifted by Aqualon Hercules, PEG6000, gifted by Clariant 
Chemicals (India) Ltd, isopropyl alcohol gifted by Deepak 
Fertilizers and Petrochemicals Corporation Ltd, methylene 
chloride gifted by Gujarat Fluro Chemicals Ltd, silicified MCC 
(Prosolv HD90) gifted by JRS Pharma, kollidon CL gifted by BASF, 
Ludwigshafen, Germany, sodium stearyl fumarate gifted by Rank 
Organics Chemical Pvt Ltd. 
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Methods 
Preparation of MS CR pellets with PL coatings 
MS CR pellets were composed of four parts, namely Celphere CP 203, 
seal coating, DL, CR-coating layer and protective coating layer 
successively. All the layers were prepared in a FBD (table 1) by 
solution layering methods. The formulation includes preparation of 
seal coated solution and coated this solution on Celphere CP 203 
after completion of seal coating, DL solution and CR coated solution 
was prepared and coated on seal coated pellets, finally protective 
coating was given on the CR pellets to prevent cracking of functional 
layers during compression, after preparation of protective coated 
pellets prelubrication and lubrication was done followed by 
compression. Seal-coated pellets, DL pellets, CR coated pellets and 
protectively coated pellets were dried for 30 min at 45 °C and then 
weighed to calculate the weight gain when their temperature 
reached room temperature. 
Preparation of seal coated pellets 
Isopropyl alcohol and methylene chloride solvents were taken on a 
vessel, added ethocel standard 10 premium slowly to the solvent 
system with continuous stirring for 30 min, got a clear solution and 
acetyl tributyl citrate was added slowly to the above solution and 
mixed for 30 min got a clear solution. Selected core pellets were 
loaded in FBP (Glatt 1.1) and coated these core pellets with a seal 
coating solution by using 1.5 mm nozzle, and parameters were 
compiled below table (1). After completion of coating, seal coated 
pellets were dried at 45⁰C for 30 min. 
Preparation of DL pellets 
Purified water was taken in a vessel equipped with propeller stirrer 
and added HPMC 5 cps slowly to the purified water with continued 
stirring for 30 min, it formed a clear solution and then added MS 
slowly to the above solution, mixed for 30 min, it formed a clear 
solution, and loaded this DL solution on seal coated pellets, the 
parameters were compiled in table (1). 
Preparation of CR pellets 
Isopropyl alcohol was taken on a vessel with stirrer and added ethocel 
standard 10 premium slowly to the solvent with continued stirring for 
10 min and added methylene chloride solvent while stirring and 
continued stirring for 30 min and added Klucel LF slowly to the above 
solution to continue stirring for 30 min and formed a clear solution 
finally added purified water to the solution with continued stirring for 
30 min. This clear solution was coated on DL pellets to get CR pellets, 
the parameters were compiled in the table (1). 
Preparation of PL pellets 
PL coating was done by dissolving the Klucel LF, PEG 6000, HPMC 5 
cps, GG and XG in purified water and coated on CR pellets by a 
solution layering method in FBP method, the parameters were 
compiled in table (1). 
Characterization of PL coated pellets and precompression blend 
Apparent bulk density  
The bulk density of a powder is the ratio of the mass of an untapped 
powder sample and its volume, including the contribution of the 
interparticulate void volume. Hence, the bulk density depends on both 
the density of powder particles and the spatial arrangement of particles 
in the powder bed. The bulk density is expressed in grams per ml (g/ml). 
The bulk density was determined by transferring the accurately 
weighted amount of sample to the graduated measuring cylinder 
and noted initial volume. The bulk density of the sample was then 





Table 1: Seal coating, DL, CR coating and PL coating process parameters 
Process parameter Seal coating DL CR coating PL coating 
Coating type Non-aqueous coating Aqueous coating Non-aqueous coating Aqueous coating 
Product temperature (⁰C) 30±5 45±5 30±5 45±5 
Atomization (Bar) 0.5-1.0 1-2.5 0.5-1.0 1-2.5 
Spray rate(g/min) 5-20 5-15 5-15 5-20 
Fluidization (CFM) 5-10 5-10 5-10 5-10 
Wurster (mm) 18 18 18 18 
The protective coated pellets were mixed with extragranular excipients, lubricants and prepared final blend, the final lubricated blend was 
compressed into tablets. The composition of pellets and tablets were compiled in the table (2) and table (3). 
 
Table 2: MS 200 mg CR pellet formula 
S. No. Ingredients Quantity/unit mg) 
1.  Celphere CP 203, (150-300µ) 68.00 
Seal coating 
2.  Ethocel standard 10 premium 11.90 
3.  Acetyltributyl citrate 1.70 
4.  Isopropyl alcohol 140.00 
5.  Methylene chloride 70.00 
 Weight of seal coated pellets 81.60 
DL 
6.  MS 190.00 
7.  HPMC 2910 5cps  9.50 
8.  Purified water 950.30 
  Weight of DL pellets  281.10 
CR Coating 
9.  Ethocel standard 10 premium 75.83 
10.  Klucel LF 19.17 
11.  Isopropyl alcohol 1340.08 
12.  Methylene chloride 670.04 
13.  Purified water 349.52 
  Weight of CR coated pellets  376.10 
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Table 3: MS 200 mg CR MUPS tablet formula 
S. No. Ingredients [mg/tablet] Formulations 
MTP1a MTP2b MTP3c MTP4d MTP5e 
CR pellets 376.10 376.10 376.10 376.10 376.10 
1 Klucel LF 37.61 --- --- --- --- 
2 PEG 6000 -- 37.61 --- --- --- 
3 HPMC 5 cps -- --- 37.61 --- --- 
4 GG -- --- --- 37.61 --- 
5 XG -- --- --- --- 37.61 
Weight of PL pellets 413.71 413.71 413.71 413.71 413.71 
Extragranular      
6 Prosolv HD 90 378.79 378.79 378.79 378.79 378.79 
7 PEG 6000 50.00 50.00 50.00 50.00 50.00 
8 Kollidon CL 150.00 150.00 150.00 150.00 150.00 
9 Sodium stearyl fumarate 7.50 7.50 7.50 7.50 7.50 
Weight of Tablet 1000 1000 1000 1000 1000 
MTP1ais MS 200 mg CR MUPS tablets with Klucel LF PL coating, MTP2bis MS 200 mg CR MUPS tablets with PEG 6000 PL coating, MTP1cis MS 200 mg CR 
MUPS tablets with HPMC 5 cps PL coating, MTP1dis MS 200 mg CR MUPS tablets with GG PL coating, MTP1eis MS 200 mg CR MUPS tablets with XG PL 
coating. 
 
Tapped density (g/ml)  
The tapped density was determined by using tapped density 
apparatus make. Electro lab, Model ETD-1020, the procedure 
involves the weighed quantity of sample was taken in 250 ml a 
measuring cylinder and the cylinder was kept on cylinder holder 
and allowed to tap for 10, 500, and 1250 taps on the same powder 
sample and read the corresponding volumes V10, V500, and V1250 
to the nearest graduated unit. If the difference between V500 and 
V1250 is less than or equal to 2 % V1250 is the tapped volume If the 
difference between V500 and V1250 exceeds 2 % repeated in 
increments such as 1250 taps, until the difference between 
succeeding measurements is less than or equal to 2 %. Fewer taps 
may be appropriate for some samples when validated. The tapped 





Compressibility index or Carr’s index  
The percentage compressibility of the drug was determined by using 
the following formula. It is measured in percentage (%) and limits 
were presented in table (4) [17]. 





Table 4: Limits for Carr’s index 






32-37 Very poor 
>38 Very, very poor 
 
Table 5: Limits for Hausner’s ratio 






1.46-.59 Very poor 
>1.60 Very, very poor 
 
Hausner’s ratio 
It related to the flow properties of powder samples and is measured 
by the ratio of tapped density to bulk density or ratio of bulk volume 
to tapped volume, it is related to interparticle friction. Limits of 
hausners ratio were presented in table (5) [17]. 







Angle of repose  
The angle of repose is a characteristic related to interparticulte 
friction or resistance to movement between particles. It is the 
constant, three-dimensional angle (relative to horizontal base) 
assumed by a cone-like a pile of material formed by any of several 
different methods. The limits of the angle of repose were presented 
in table (6) [18-20]. 
Tan Ø = (h/r) 
Where’ h’ is the height of the cone  
‘R’ is the radius of the cone. 
Evaluation of compressed tablets 
Thickness (mm)  
The thickness of the tablets was determined by using vernier 
calipers. Three tablets were picked up randomly and thickness was 
measured individually using the formula [21]. 
Thickness=MSR+[VSR×0.01]  
Where,  
MSR= Main scale reading  
VSR= Vernier scale reading 
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Table 6: Limits for angle of repose (degrees) 
Flow character Angle of repose (degrees) 
Excellent 25-30 
Good 31-35 
Fair-aid not needed 36-40 
Passable-may hang up 41-45 
Poor-must agitate, vibrate 46-55 
Very poor 56-65 
Very, very poor >66 
 
Hardness (KP)  
The hardness of the tablets was determined using hardness tester 
make: Pharmatest, Type: PTB–311E. It was expressed in KP. Three 
tablets were randomly picked and the average value of hardness 
was determined [22]. 
Weight variation test  
To study weight variation, 20 tablets of each formulation were 
weighed using an electronic balance, average weights were 
calculated, individual tablet weights were compared with the 
average weight. Not more than two individual weights deviate from 
the average weight by more than percentage shown in the following 
table and the results were shown in table 7[23].  
PD= 
(W avg)–(W initial) 
(W avg)
×100 
Where, PD = Percentage deviation  
W avg = Average weight of tablets  
W initial = Individual weight of tablet. 
 
Standard weight variation (IP)  
Table 7: Limits for weight variation 
Average tablet weight (mg)  Percentage deviation (%)  
Up to 80 mg  5 
>80 mg,<250 mg  7.5 
250 mg or more   10 
 
Friability test (%)  
Friability is the measure of tablet strength. It is expressed in 
percentage (%), the friability of the tablet was determined by using 
roche friabilator. 10 tablets were initially weighed and transferred 
into the friabilator. The friabilator was operated for 100 revolutions 
(25 rpm/min), then tablets were taken out and dedusted. The 
percentage weight loss was calculated by reweighing the tablets. The 






W1 = Initial weight of the tablets  
W2 = Final weight of the tablets  
Friability limits: less than 1% is acceptable 
In vitro disintegration test  
The test was carried out on 6 tablets using digital tablet disintegration 
tester make Electrolab in purified water at 37 ⁰C±2 ⁰C [25]. 
Drug release measurements and comparisons 
Prepared MUPS pellets and tablets were subjected to in-vitro 
dissolution profiles in pH 6.8 phosphate buffer using apparatus 
II (paddle apparatus) [26], 500 ml, maintained at 37±0.5 °C.500 
ml of in pH 6.8 phosphate buffer was transferred into each 
dissolution container. MS MUPS pellets and tablets were placed 
in each of the containers, and operated dissolution apparatus at 
50 rpm for 20 h. At each specified interval of time, 5.0 ml of the 
sample was withdrawn from each container and replaced with 
equal volume of fresh pH 6.8 medium maintained at 37±0.5 °C. 
The collected sample was filtered through 0.45 μm membrane 
filter and analyzed the drug content by using ultraviolet-visible 
spectroscopy. 
In this study, we evaluated the similarity between MUPS pellets and 
final compressed tablets in the pH 6.8 phosphate buffer and tested 
any breakage of coating layer during compression. As a parameter of 
similarity evaluation, the similarity factor (f2) plays a significant role 
in comparing the dissolution profiles. f2 (shown in the following 
formula) is a logarithmic transformation of the sum-squared error of 
differences between MUPS pellets and the compressed tablets over 
all time points [27]. 
 
Log stands for logarithm based on 10. It is recommended that two 
dissolution profiles can be determined to be similar when f2 value 
exceeds 50. 
RESULTS AND DISCUSSION 
Micromeritic properties of PL pellets 
The PL pellets of all the batches (MPT1-MPT4) were evaluated for 
bulk density, tapped density, compressibility index, hausners ratio 
and angle of repose and presented in the table (8). Bulk density 
ranged from 0.698 to 0.711 g/ml, tapped density ranged from 0.735 
to 0.758 g/ml, Carr's index ranged from 4.898 to 6.201 %, and 
hausners ratio ranged from 1.052 to 1.066%. 
Based on above results it indicated that the PL pellets possess 
satisfactory flow and compressibility index. 
 
Table 8: Evaluation of PL pellets 
Formulation Description Bulk density (g/ml) Tapped density (g/ml) Carr’s index (%) Hauser’s ratio 
MPT1 Off white pellets 0.705 0.750 6.000 1.064 
MPT2 Off white pellets 0.698 0.740 5.676 1.060 
MPT3 Off white pellets 0.711 0.758 6.201 1.066 
MPT4 Off white pellets 0.702 0.745 5.772 1.061 
MPT5 Off white pellets 0.699 0.735 4.898 1.052 
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Micromeritic properties of the lubricated blend 
The lubricated blend of all the batches (MPT1-MPT4) was 
evaluated for bulk density, tapped density, compressibility 
index, hausners ratio and angle of repose and presented in table 
(9). Bulk density ranged from 0.598 to 0.621 g/ml, tapped 
density ranged from 0.728 to 0.735 g/ml, carr’s index ranged 
from 14.973 to 17.517%, and hausners ratio ranged from 1.176 
to 1.212%. 
Based on above results it indicated that the lubricated blends 
possess satisfactory flow and compressibility index. 
 
Table 9: Evaluation of lubricated blend 
Formulation Bulk density (g/ml) Tapped density (g/ml) Carr’s index (%) Hauser’s ratio Angle of repose (degrees) 
MPT1 0.619 0.728 14.973 1.176 36 
MPT2 0.598 0.725 17.517 1.212 36 
MPT3 0.621 0.735 15.510 1.184 37 
MPT4 0.615 0.730 15.753 1.187 38 
MPT5 0.610 0.728 16.209 1.193 35 
 
Process parameters for tablet compression 
Thickness of the MUPS tablets was found to be in the range of 7.5±0.021 
to 7.6±0.040 mm. The hardness of the tablets was found to 15.7±0.458 to 
16.2±0.306. Friability of all the tablets varied from 0.50±0.02 to 
0.85±0.007 % which was less than 1% as per official requirement of I. P. 
Weight variation of developed tablets indicated that no significant 
difference in weight of individual tablet from the average value.  
The drug content in all the batches of MS MUPS tablets was in the 
range of 100.1±0.351 to 101.3±1.058 i.e., within the official limits. 
These parameters presented in table (10). 
  















MPT1 7.6±0.026 15.7±0.458 0.070±0.020 1000.7±2.517 100.1±0.351 145.33±4.51 
MPT2 7.6±0.040 15.9±0.513 0.030±0.021 1000.3±1.528 100.4±1.026 138.00±2.00 
MPT3 7.5±0.032 15.8±0.702 0.047±0.015 998.7±1.528 101.3±1.058 142.67±4.04 
MPT4 7.5±0.038 16.2±0.306 0.033±0.021 998.0±1.000 101.0±0.458 127.67±0.58 
MPT5 7.5±0.021 16.2±0.300 0.040±0.015 1000.3±1.041 100.8±0.808 134.33±4.04 
The data presented are as mean values±SD, n=3 
 
Drug release measurements and comparisons 
The prepared CR pellets divided into six parts, one part was used for 
dissolution studies and other five parts were used for protective 
coating of five polymers Klucel LF, PEG 6000, HPMC 5 cps, GG and 
XG. The prepared PL coated pellets of synthetic polymers Klucel LF, 
PEG 6000, HPMC 5 cps and natural polymers GG, XG were free-
flowing, free from agglomerates. We had taken CR common pellets, 
PL pellets of five different polymers and compressed into tablets and 
compared the dissolution profiles of CR pellets, PL pellets, MUPS 
tablets compressed with CR pellets and MUPS tablets compressed 
with PL pellets. The hardness was selected 15-18 KP where MUPS 
tablets made with the CR pellets are breaking and release the drug 
faster than CR pellets. 
Effect of Klucel LF PL coating on drug release before and after 
compression of pellets 
Drug release of Klucel LF PL pellets, MUPS tablets made with Klucel 
LF PL pellets were observed that there was no significant change, 
whereas MUPS tablets made with CR pellets showing significant 
increasing in release profile it might be indicating that breakage of 
CR pellets in MUPS tablets contain CR pellets and intact of Klucel LF 
PL pellets in MUPS tablets made with Klucel LF PL pellets. The 
release profiles were compiled in table (11). 
 
Table 11: In vitro dissolution profiles of CR, Klucel LF PL coated pellets and tablets manufactured with that pellets 
Time in h % Drug dissolved  
CR pellets PL coated pellets Tablets manufactured with CR pellets Tablets manufactured with PL coated pellets 
1 11(1.67) 12(1.63) 18(2.14) 9(1.22) 
2 18(1.83) 18(1.26) 23(2.07) 17(1.03) 
3 23(1.21) 24(1.75) 35(2.37) 24(1.21) 
4 28(1.64) 29(2.07) 43(2.64) 27(1.75) 
6 38(1.83) 39(1.79) 53(2.34) 40(1.38) 
8 47(2.34) 49(1.94) 62(2.37) 50(2.59) 
10 56(1.64) 58(1.94) 71(1.51) 56(2.14) 
12 65(1.47) 66(1.94) 82(1.72) 68(1.05) 
16 81(1.47) 81(2.17) 90(1.75) 82(1.38) 
20 90(1.79) 90(1.72) 97(0.82) 93(1.37) 
f2   88.6 45.26 81.83 
The data presented are as mean values±SD, n=6 
 
Effect of PEG 6000 PL coating on drug release before and after 
compression of pellets 
Drug release of PEG 6000 PL pellets, MUPS tablets made with PEG 
6000, MUPS tablets made with CR pellets were observed that there 
was a significant change in release profile it might be indicates that 
breakage of CR pellets, PEG 6000 PL pellets in MUPS tablets. It 
indicated that PL coating with PEG 6000 may not suitable to protect 
pellets from compression breakage. The release profiles were 
compiled in table (12). 
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Table 12: In vitro dissolution profiles of CR, PEG 6000 PL coated pellets and tablets manufactured with that pellets 
Time in h % Drug dissolved  
CR pellets PL coated pellets Tablets manufactured with CR pellets  Tablets manufactured with PL coated pellets 
1 11(1.67) 10(1.79) 18(2.14) 15(2.25) 
2 18(1.83) 17(2.32) 23(2.07) 21(2.88) 
3 23(1.21) 22(2.50) 35(2.37) 34(2.25) 
4 28(1.64) 27(1.60) 43(2.64) 41(2.73) 
6 38(1.83) 36(2.07) 53(2.34) 49(2.48) 
8 47(2.34) 45(2.07) 62(2.37) 60(2.58) 
10 56(1.64) 55(1.83) 71(1.51) 68(2.32) 
12 65(1.47) 63(1.83) 82(1.72) 75(2.58) 
16 81(1.47) 79(2.07) 90(1.75) 81(1.21) 
20 90(1.79) 91(1.41) 97(0.82) 97(1.05) 
f2   87.37  49.92 
The data presented are as mean values±SD, n=6 
 
Effect of HPMC 5 cps PL coating on drug release before and after 
compression of pellets 
Drug release of HPMC 5 cps PL pellets, MUPS tablets made with 
HPMC 5 cps PL pellets were observed that there was no significant 
change whereas MUPS tablets made with CR pellets showing 
significant increasing in release it might be indicates that breakage 
of CR pellets in MUPS tablets contain CR pellets and intact of HPMC 5 
cps PL pellets in MUPS tablets made with HPMC 5 cps PL pellets. The 
release profiles were compiled in table 13. 
 
Table 13: In vitro dissolution profiles of CR, HPMC 5 cps PL coated pellets and tablets manufactured with that pellets 
Time in h % Drug dissolved  
CR pellets PL coated pellets Tablets manufactured with CR pellets  Tablets manufactured with PL coated pellets 
1 11(1.67) 10(1.51) 18(2.14) 10(0.75) 
2 18(1.83) 18(1.26) 23(2.07) 20(1.21) 
3 23(1.21) 22(1.51) 35(2.37) 24(0.82) 
4 28(1.64) 26(1.05) 43(2.64) 29(1.64) 
6 38(1.83) 37(1.75) 53(2.34) 40(0.52) 
8 47(2.34) 45(1.97) 62(2.37) 48(1.10) 
10 56(1.64) 54(1.86) 71(1.51) 57(1.55) 
12 65(1.47) 64(2.56) 82(1.72) 65(1.86) 
16 81(1.47) 80(1.10) 90(1.75) 82(1.38) 
20 90(1.79) 88(2.32) 97(0.82) 91(0.75) 
f2   86.93 45.26 89.35 
The data presented are as mean values±SD, n=6 
 
Effect of GG PL coating on drug release before and after 
compression of pellets 
Drug release of GG PL pellets, MUPS tablets made with GG PL 
pellets were observed that there was no significant change 
whereas MUPS tablets made with CR pellets showing significant 
increasing in release, it might be indicates that breakage of CR 
pellets in MUPS tablets contain CR pellets and intact of GG PL 
pellets in MUPS tablets made with GG PL pellets. The release 
profiles were compiled in table (14). 
 
Table 14: In vitro dissolution profiles of CR, GG PL coated pellets and tablets manufactured with that pellets 
Time in h % Drug dissolved  
CR pellets PL coated pellets Tablets manufactured with CR pellets  Tablets manufactured with PL coated pellets 
1 11(1.67) 9(1.37) 18(2.14) 10(0.52) 
2 18(1.83) 15(1.03) 23(2.07) 15(0.75) 
3 23(1.21) 20(1.22) 35(2.37) 21(0.98) 
4 28(1.64) 24(1.22) 43(2.64) 25(0.55) 
6 38(1.83) 32(1.97) 53(2.34) 33(0.84) 
8 47(2.34) 42(1.51) 62(2.37) 41(1.05) 
10 56(1.64) 51(1.86) 71(1.51) 49(1.03) 
12 65(1.47) 60(1.55) 82(1.72) 59(0.84) 
16 81(1.47) 79(0.89) 90(1.75) 77(1.21) 
20 90(1.79) 87(1.10) 97(0.82) 85(1.17) 
f2   69.11 45.26 66.44 
The data presented are as mean values±SD, n=6 
 
Effect of XM PL coating on drug release before and after 
compression of pellets 
Drug release of XM PL pellets, MUPS tablets made with XM PL pellets 
were observed that there was no significant change whereas MUPS 
tablets made with CR pellets showing significant increasing in 
release it might be indicates that breakage of CR pellets in MUPS 
tablets contain CR pellets and intact of XM PL pellets in MUPS tablets 
made with XM PL pellets. The release profiles were compiled in the 
table (15). 
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Table 15: In vitro dissolution profiles of CR, XM PL coated pellets and tablets manufactured with that pellets 
Time in h % Drug dissolved  
CR pellets PL coated pellets Tablets manufactured with CR pellets  Tablets manufactured with PL coated pellets 
1 11(1.67) 11(1.86) 18(2.14) 9(1.03) 
2 18(1.83) 17(1.63) 23(2.07) 16(1.05) 
3 23(1.21) 22(1.63) 35(2.37) 21(1.05) 
4 28(1.64) 28(0.89) 43(2.64) 27(1.05) 
6 38(1.83) 37(1.47) 53(2.34) 35(0.84) 
8 47(2.34) 48(1.05) 62(2.37) 46(1.22) 
10 56(1.64) 55(1.38) 71(1.51) 55(1.76) 
12 65(1.47) 65(1.26) 82(1.72) 66(1.76) 
16 81(1.47) 80(1.47) 90(1.75) 82(1.21) 
20 90(1.79) 91(1.05) 97(0.82) 90(1.17) 
f2   92.47 45.26 85.25 
The data presented are as mean values±SD, n=6 
 
The results obtained from the flow evaluation of The PL pellets, 
lubricated blend, it was found that the flow rate, carr’s index, hauser’s 
ratio and angle of repose had values that comply with the official 
standard for good powder flowability [17-20]. The results of 
compression parameters of all batches (MTP1-MTP5) were well 
within the limits of the official standards. Tablet thickness is an 
important quality control parameter for packaging of tablets in 
container blisters, the void space in container pack, blister toolings 
selection depends on thickness of the tablets. Tablets thickness can be 
varied with particle size distribution, density of the granules, punches, 
dies and hardness. From the results, the tablets exhibited good 
uniformity of thickness and conform to the official standard limits. 
The weight variation of tablets contributes to the dose uniformity of a 
drug [23], if the drug is higher dose more than 25 mg and formulation 
contain 25% of active, content uniformity of tablets can be checked by 
using weight variation method. The variation in tablet weight may be 
due to poor flow of granules, lack of uniformity in granule size, 
compression process variables such as feed frame paddle speed and 
press speed. The data obtained for weight uniformity test indicate that 
the tablets possess significant dose uniformity. 
All formulated tablets had a hardness within the range of 15-18 KP, 
hardness play an important role on dissolution profiles depends on 
whether dosage form is matrix tablets or MUPS tablets. In case of 
matrix tablets if increase hardness, the rate of dissolution will 
decrease, whereas in case of MUPS tablets if increase hardness rate 
of dissolution increases and hence hardness play a very important 
role during compression. The hardness data indicated that all 
formulations having a good uniform and narrow range [22]. The 
results of friability indicated that all formulations had friability 
within the official limits ≤ 1% [24]. Friability is a routine test per 
compendial requirements for tablets. A target of NMT 1.0% w/w of 
mean weight loss assures a low impact on patient safety and efficacy 
and minimize customer complaints. 
The CR pellets, PL coated pellets, Tablets manufactured with CR pellets, 
Tablets manufactured with PL coated pellets dissolutions were studied 
and comparatively compiled in tables. The drug release profile is 
important for bioavailability (BA); therefore, it is critical. Since in vitro 
drug release is a surrogate for in vivo performance, rate drug release 
depends on different factors like type of dissolution apparatus, 
dissolution media, pH of media, a method of dissolution, the composition 
of the polymer, a percentage weight gain of CR coating, size of core 
pellets, extragranular excipients. Hence above all formulations were 
used same factors except PL coating. The results of dissolution profiles 
indicated that drug was released in a controlled manner and released 
above 90% in 20 h in all formulations. The dissolution profiles of tablets 
manufactured with CR pellets had fasted release compared to pellets 
alone, it indicates that break the pellets during compression without any 
protective layer coating. 
The dissolution profiles of tablets manufactured with GG, XG, Klucel 
LF, HPMC 5 cps PL coated pellets similar to pellets alone, there was 
no significant difference in dissolution profiles, it indicated that PL 
coatings were protecting pellets during compression. Binding 
nature, plastic nature, mechanical properties of these polymers may 
protect pellets from compression forces without retarding 
dissolution profiles. The dissolution profiles of tablets manufactured 
with PEG 6000 PL coated pellets were faster than pellets alone, it 
indicates PEG 6000 PL coating was not sufficient to protect pellets 
from compression force. It may be due to low binding nature, less 
mechanical properties of PEG 6000. The results of dissolution 
profiles indicate that GG, XG, Klucel LF, HPMC 5 cps PL coated pellets 
were good candidates for manufacturing of MUPS tablets. 
CONCLUSION 
MS CR tablets were prepared successfully by using ethyl cellulose and 
HPMC 5cps used as release-modifying excipients and low viscous natural 
or synthetic binders like Klucel LF, PEG 6000, HPMC 5 cps, GG and XM as 
PL coating agents. The flow properties of pellets and the lubricated blend 
were evaluated and found to be satisfactory. The process parameters of 
MS MUPS tablets were found to be well within limits. 
Based on comparative dissolution profiles of MUPS tablets, CR 
pellets and PL coating pellets it was found that by applying low 
viscous natural or synthetic binders like Klucel LF, HPMC 5 cps, GG 
and XM on functional coating given good protection to functional 
coating layers from damage during compression. Hence it can be 
concluded that this approach is a very effective and potent strategy 
for manufacturing of MUPS tablets. Whereas very low viscous 
polymers PEG 6000 not able to protect functional coating layers of 
pellets from damage during compression. 
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